Heptares makes Daniel Grau president
This article was originally published in Scrip
GPCR drug discovery company Heptares Therapeutics has appointed Daniel Grau president. Mr Grau has been a senior advisor to Heptares since 2010, and will report to CEO Malcolm Weir. Mr Grau previously served as president and CEO of Cortria Corporation, and is currently a member of the product advisory board of Concert Pharmaceuticals.